IPHA Quote, Financials, Valuation and Earnings

DBV Technologies SA has a net margin of -- compared to Innate Pharma SA's net margin of --. Innate Pharma SA's return on equity of -72.79% beat DBV Technologies SA's return on equity of -280.59%.

Innate Pharma SA has a consensus price target of $5.15, signalling upside risk potential of 194.51%. On the other hand DBV Technologies SA has an analysts' consensus of $40.03 which suggests that it could grow by 107.86%. Given that Innate Pharma SA has higher upside potential than DBV Technologies SA, analysts believe Innate Pharma SA is more attractive than DBV Technologies SA.

Innate Pharma SA has a beta of -0.018, which suggesting that the stock is 101.755% less volatile than S&P 500. In comparison DBV Technologies SA has a beta of -1.166, suggesting its less volatile than the S&P 500 by 216.581%.

Innate Pharma SA has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. DBV Technologies SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Innate Pharma SA pays -- of its earnings as a dividend. DBV Technologies SA pays out -- of its earnings as a dividend.

Innate Pharma SA quarterly revenues are --, which are smaller than DBV Technologies SA quarterly revenues of --. Innate Pharma SA's net income of -- is lower than DBV Technologies SA's net income of -$33M. Notably, Innate Pharma SA's price-to-earnings ratio is -- while DBV Technologies SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Innate Pharma SA is 22.60x versus -- for DBV Technologies SA. Usually stocks with elevated PS ratios are considered overvalued.

Inventiva SA has a net margin of -- compared to Innate Pharma SA's net margin of --. Innate Pharma SA's return on equity of -72.79% beat Inventiva SA's return on equity of --.

Innate Pharma SA has a consensus price target of $5.15, signalling upside risk potential of 194.51%. On the other hand Inventiva SA has an analysts' consensus of $15.33 which suggests that it could grow by 229.75%. Given that Inventiva SA has higher upside potential than Innate Pharma SA, analysts believe Inventiva SA is more attractive than Innate Pharma SA.

Innate Pharma SA has a beta of -0.018, which suggesting that the stock is 101.755% less volatile than S&P 500. In comparison Inventiva SA has a beta of 0.708, suggesting its less volatile than the S&P 500 by 29.184%.

Innate Pharma SA has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Inventiva SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Innate Pharma SA pays -- of its earnings as a dividend. Inventiva SA pays out -- of its earnings as a dividend.

Innate Pharma SA quarterly revenues are --, which are smaller than Inventiva SA quarterly revenues of --. Innate Pharma SA's net income of -- is lower than Inventiva SA's net income of --. Notably, Innate Pharma SA's price-to-earnings ratio is -- while Inventiva SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Innate Pharma SA is 22.60x versus 27.07x for Inventiva SA. Usually stocks with elevated PS ratios are considered overvalued.

Nanobiotix SA has a net margin of -- compared to Innate Pharma SA's net margin of --. Innate Pharma SA's return on equity of -72.79% beat Nanobiotix SA's return on equity of --.

Innate Pharma SA has a consensus price target of $5.15, signalling upside risk potential of 194.51%. On the other hand Nanobiotix SA has an analysts' consensus of $14.75 which suggests that it could fall by -32.14%. Given that Innate Pharma SA has higher upside potential than Nanobiotix SA, analysts believe Innate Pharma SA is more attractive than Nanobiotix SA.

Innate Pharma SA has a beta of -0.018, which suggesting that the stock is 101.755% less volatile than S&P 500. In comparison Nanobiotix SA has a beta of 0.704, suggesting its less volatile than the S&P 500 by 29.588%.

Innate Pharma SA has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Nanobiotix SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Innate Pharma SA pays -- of its earnings as a dividend. Nanobiotix SA pays out -- of its earnings as a dividend.

Innate Pharma SA quarterly revenues are --, which are smaller than Nanobiotix SA quarterly revenues of --. Innate Pharma SA's net income of -- is lower than Nanobiotix SA's net income of --. Notably, Innate Pharma SA's price-to-earnings ratio is -- while Nanobiotix SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Innate Pharma SA is 22.60x versus 32.25x for Nanobiotix SA. Usually stocks with elevated PS ratios are considered overvalued.

Valneva SE has a net margin of -- compared to Innate Pharma SA's net margin of -150.82%. Innate Pharma SA's return on equity of -72.79% beat Valneva SE's return on equity of -56.21%.

Innate Pharma SA has a consensus price target of $5.15, signalling upside risk potential of 194.51%. On the other hand Valneva SE has an analysts' consensus of $11.51 which suggests that it could grow by 46.12%. Given that Innate Pharma SA has higher upside potential than Valneva SE, analysts believe Innate Pharma SA is more attractive than Valneva SE.

Innate Pharma SA has a beta of -0.018, which suggesting that the stock is 101.755% less volatile than S&P 500. In comparison Valneva SE has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Innate Pharma SA has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Valneva SE offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Innate Pharma SA pays -- of its earnings as a dividend. Valneva SE pays out -- of its earnings as a dividend.

Innate Pharma SA quarterly revenues are --, which are smaller than Valneva SE quarterly revenues of $34.4M. Innate Pharma SA's net income of -- is lower than Valneva SE's net income of -$51.8M. Notably, Innate Pharma SA's price-to-earnings ratio is -- while Valneva SE's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Innate Pharma SA is 22.60x versus 3.68x for Valneva SE. Usually stocks with elevated PS ratios are considered overvalued.